Home
Unichem Laboratories Ltd PE Ratio

Unichem Laboratories Ltd
NSE: UNICHEMLAB
PE
Key Highlights
- The P/E Ratio of Unichem Laboratories Ltd is 57.3 as of 04 Apr 13:53 PM .
- The P/E Ratio of Unichem Laboratories Ltd changed from 63.4 on March 2021 to 0 on March 2024 . This represents a CAGR of -100.00% over 4 years.
- The Latest Trading Price of Unichem Laboratories Ltd is ₹ 656.8 as of 04 Apr 13:43 .
- The PE Ratio of Pharmaceuticals Industry has changed from 21.0 to 40.0 in 5 years. This represents a CAGR of 13.75%.
- The PE Ratio of Automobile industry is 20.3. The PE Ratio of Finance industry is 17.8. The PE Ratio of IT - Software industry is 30.2. The PE Ratio of Pharmaceuticals industry is 40.0. The PE Ratio of Retail industry is 157.6. The PE Ratio of Textiles industry is 37.1 in 2024.
Historical P/E Ratio of Unichem Laboratories Ltd
The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share. P/E Ratio Formula P/E ratio = (CMP of share/ Earning per share) Types of Price to Earning Ratio 1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance. 2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.
Historical P/E Ratio of Unichem Laboratories Ltd
Company Fundamentals for Unichem Laboratories Ltd

Unichem Laboratories Ltd
NSE: UNICHEMLAB
Share Price
Market Price of Unichem Laboratories Ltd
1M
1Y
3Y
5Y
Last Ten Days Market Price
Date | |
---|---|
03 Apr 2025 | 689 |
02 Apr 2025 | 684.9 |
01 Apr 2025 | 698.45 |
28 Mar 2025 | 692.8 |
27 Mar 2025 | 695.35 |
26 Mar 2025 | 687.95 |
25 Mar 2025 | 694.15 |
24 Mar 2025 | 701 |
21 Mar 2025 | 710.2 |
20 Mar 2025 | 664.55 |
SWOT Analysis Of Unichem Laboratories Ltd
BlinkX Score for Unichem Laboratories Ltd
Asset Value vs Market Value of Unichem Laboratories Ltd
Market Value
₹ 0
Asset Value
₹ 0
* All values are in ₹ crores
Competitive Comparison of P/E Ratio
Company | Market Cap | PE Ratio |
---|
Unichem Laboratories Ltd | 4850 | 57.32 |
Sun Pharmaceutical Industries Ltd | 424706 | 36.0 |
Divis Laboratories Ltd | 152946 | 74.0 |
Cipla Ltd | 120751 | 24.2 |
Torrent Pharmaceuticals Ltd | 109983 | 59.1 |
Mankind Pharma Ltd | 100168 | 49.1 |
Company | |
---|---|
Unichem Laboratories Ltd | 4850 |
Sun Pharmaceutical Industries Ltd | 424706 |
Divis Laboratories Ltd | 152946 |
Cipla Ltd | 120751 |
Torrent Pharmaceuticals Ltd | 109983 |
Mankind Pharma Ltd | 100168 |
PE Ratio of Unichem Laboratories Ltd Explained
₹4850
Market cap
₹-37
Earnings
57.3X
PE Ratio
The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share.
P/E Ratio Formula
P/E ratio = (CMP of share/ Earning per share)
Types of Price to Earning Ratio
1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance.
2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.
PE Ratio of Pharmaceuticals Industry over time
PE Ratio of Top Sectors
Historical Market Cap of Unichem Laboratories Ltd
Market Cap or market capitalisation refers to metrics that are used to measure a company's size. It is defined as the total market value of a company's outstanding shares of stock. Formula of Market Cap: Market Capital = N * P Here, N for the outstanding shares P refers to the closing price of the company's shares. Types of Companies based on Market Cap: - Small-Cap stocks: Up to 500 Crore - Mid-Cap Stocks: From Rs.500 crore up to Rs.7,000 crore - Large-Cap Stocks: From Rs.7,000 crore up to Rs.20,000 crore
Historical Market Cap of Unichem Laboratories Ltd
Historical Revenue, EBITDA and Net Profit of Unichem Laboratories Ltd
Revenue term means the amount of money a company earns from its primary business activities such as the sales of its products & services.\r\r\n\r\r\nTypes of Revenue:\r\r\n\r\r\n1. Operating revenue: It refers to the income generated from the core business activities, which are sales of goods or services rendered.\r\r\n\r\r\n2. Non-Operating revenue: It is the income generated from secondary sources unrelated to the primary business. Examples include rents, dividends, interest, and royalty fees.\r\r\n\r\r\nFormula for Revenue:\r\r\n\r\r\nThe formula for calculating revenue is based on two goods & services:\r\r\n\r\r\nFor goods:\r\r\nRevenue = Avg unit price x Number of Units sold\r\r\n\r\r\nFor services:\r\r\nRevenue = Avg unit price x Number of Customers served.PBIDT stands for Profit Before Interest, Depreciation, and Taxes. It is a financial metric that measures a company's profitability before accounting for interest expenses, depreciation of assets, and taxes. Formula to calculate PBIDT: PBIDT = Net Income + Interest + Depreciation + Taxes or PBIDT = Operating Income + Depreciation + Taxes PBIDT vs EBITDA vs EBIT vs EBT: Here is a brief explanation of the differences: - PBIDT (Profit Before Interest, Depreciation, and Taxes) includes taxes in its calculation, unlike EBITDA. - EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) excludes taxes and interest, focusing on operational performance. - EBIT (Earnings Before Interest and Taxes) excludes interest and taxes, providing a measure of core operational profitability. - EBT (Earnings Before Taxes) includes all operating income but does not account for interest expenses. Conclusion: PBIDT, similar to EBITDA, is a measure of operational profitability but includes taxes in its calculation.Net profit is the amount of money a company retains after accounting for all expenses, depreciation, interest, taxes, and other deductions.\r\r\n\r\r\nNet Profit formula is expressed as:\r\r\n\r\r\nNet Profit = Total Revenue - Total Expense\r\r\n\r\r\nNet Profit Margin Ratio:\r\r\n\r\r\nNet Profit Margin Ratio = Net Profit / Total Revenue
Historical Revenue, EBITDA and Net Profit of Unichem Laboratories Ltd
Revenue
EBITDA
Net Profit
Historical Dividend Payout of Unichem Laboratories Ltd
Dividend payout refers to the total dividends paid to shareholders relative to the company's earnings. It is a financial measure that determines the percentage of earnings paid out to existing shareholders as dividends. How to calculate Dividend Payout Ratio? The dividend payout ratio formula is as follows: DPR = Dividends paid / Net earnings With the dividend payout ratio, you can understand the company's priorities. It is an important metric that allows you to easily check DPR online.
Historical Dividend Payout of Unichem Laboratories Ltd
About Unichem Laboratories Ltd
- Unichem Laboratories Limited is an India-based pharmaceutical company, which manufactures active pharmaceutical ingredients.
- The company operates through four divisions, namely Unichem Pharma Division, Unichem Specialities Division, Unisearch Division and Neu-Foreva Division.
- The company is headquartered in Mumbai with five manufacturing facilities located at Roha in Maharashtra, Goa, Ghaziabad in Uttar Pradesh, Pithampur in Madhya Pradesh and Baddi in Himachal Pradesh. The company's facilities enjoy credible certifications, the Goa plant was approved by UK MHRA, MCC (South Africa), WHO (Geneva) and TGA (Australia).
- The Baddi plant was approved by UK MHRA and MCC (South Africa).
- The company received ISO 9001:2000 for all their plants and corporate office.
Unichem Laboratories Ltd News Hub
Board of Unichem Laboratories appoints CFO
The Board of Unichem Laboratories at its meeting held on 08 August 2024 has approved appointment of
Read more
08 Aug 24
Unichem Laboratories reports consolidated net profit of Rs 9.26 crore in the June 2024 quarter
Net profit of Unichem Laboratories reported to Rs 9.26 crore in the quarter ended June 2024 as again
Read more
08 Aug 24
Unichem Labs gains on proposal to consolidate USA generics formulations business under one entity
In an exchange filing made before market hours today, the company said that its board will consider
Read more
23 Sept 24
Board of Unichem Laboratories to consider proposal for consolidation of generic formulations biz in US
The Board of Unichem Laboratories will meet on 30 September 2024 to consider and approve integration
Read more
23 Sept 24